Related Experiment Videos
Polyneuropathies associated with IgM monoclonal gammopathies
J J Kelly1, L S Adelman, E Berkman
1Department of Neurology, Tufts Medical School, Boston.
Archives of Neurology
|December 1, 1988
Summary
This study shows that IgM monoclonal gammopathies targeting myelin-associated glycoprotein (MAG) cause a specific type of polyneuropathy. Treatment that lowers M protein levels effectively improved symptoms in these patients.
Area of Science:
- Neurology
- Immunology
- Oncology
Background:
- IgM monoclonal gammopathies are associated with various neuropathies.
- Myelin-associated glycoprotein (MAG) is a potential target in some IgM-related neuropathies.
Purpose of the Study:
- To investigate the clinical characteristics and treatment response of patients with IgM monoclonal gammopathies.
- To determine the role of M protein reactivity to MAG in the pathogenesis of polyneuropathy.
Main Methods:
- Studied ten patients with IgM monoclonal gammopathies, divided into MAG-reactive and non-reactive groups.
- Clinical and laboratory analyses were performed to characterize the neuropathy.
- Assessed patient response to immunosuppressive therapy targeting M protein levels.
Main Results:
- MAG-reactive patients exhibited homogeneous neuropathy, unlike the varied presentation in non-reactive patients.
- Both groups showed significant improvement with immunosuppressive therapy.
- Therapy led to a reduction in serum M protein concentration.
Conclusions:
- The homogeneity and treatment response in MAG-reactive patients suggest IgM M protein directly causes nerve fiber damage.
- IgM M protein is the proximate cause of polyneuropathy in MAG-reactive individuals.
- Immunosuppressive therapy is effective for IgM-related polyneuropathy by reducing M protein levels.